Dóra Bajcsi

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Rajiv Agarwal, Wanzhu Tu, Alfredo E. Farjat et al. · Annals of Internal Medicine · 2023 · 88 citations

Medicine, Pharmacology, Pharmacotherapy +17

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

Ellen Burgess, Rajiv Agarwal, Stefan D. Anker et al. · Diabetes Care · 2022 · 35 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis

Nóra Garam, Zoltán Prohászka, Ágnes Szilágyi et al. · Clinical Kidney Journal · 2019 · 28 citations · Full text

Medicine, Nephrology, Pathology +17

C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy

Nóra Garam, Zoltán Prohászka, Ágnes Szilágyi et al. · Orphanet Journal of Rare Diseases · 2019 · 23 citations · Full text

Medicine, Nephrology, Pathology +17